Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-02-23

Clinical Trial Update: A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes. [Phase 3]

View source ↗

Summary

A completed Phase 3 study evaluating the acute effects of vildagliptin on gastric emptying in patients with Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vildagliptin (vildagliptin)

Snippet

Sponsor: Novartis | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED